公开(公告)号：US20220135667A1

公开(公告)日：2022-05-05

申请号：US17427823

申请日：2020-02-04

Applicant: RIJSUNIVERSITEIT GRONINGEN ,  DSM IP ASSETS B.V. ,  ACADEMISCH ZIEKENHUIS GRONINGEN

Inventor： Gerard DIJKSTRA ,  Klaas Nico FABER ,  Hermanus Jozef Martinus HARMSEN ,  Robert STEINERT ,  Wilbert SYBESMA ,  Araksya TOPCHYAN

IPC: C07K16/24 ,  A61P29/00 ,  A61K31/525 ,  A61P1/00

Abstract: The present invention relates to pharmaceutical combinations of at least one TNF inhibitor and riboflavin to treat patients suffering from inflammatory bowel disease (IBD) or other inflammatory conditions (such as rheumatoid arthritis, ankylosing spondylitis, psoriasis, lupus erythematous and multiple sclerosis). This invention also relates to additive and/or combinations of at least one TNF inhibitor and riboflavin. This invention is also related to a method for the treatment or prophylaxis of IBD, which method comprises administering a therapeutically effective amount of TNF inhibitor and riboflavin.